guselkumab vs tildrakizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 p19 · full Psoriasis pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
NCT02203032 · Phase 3 · completed
In patients who had not responded well enough to ustekinumab, switching to guselkumab under randomized, blinded conditions produced significantly more visits with clear or almost-clear skin than staying on ustekinumab, a clinically meaningful and statistically significant result in a study designed and blinded to make that comparison fairly.
Next expected readout: December 2026 · NCT05004727 (registry estimate)
Reported efficacy
Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40: Primary endpoint (NAVIGATE trial), mean number of visits Week 28-40 with IGA 0/1 and >=2-grade improvement: guselkumab 1.5 (SD 1.57, n=135) vs continued ustekinumab 0.7 (SD 1.26, n=133); row mean score test P<0.001. (met)
Result source: NCT02203032
tildrakizumab · Ilumya
Marketed by Sun Pharmaceutical Industries and partners
NCT01729754 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (N=1,090) in moderate-to-severe plaque psoriasis. The primary efficacy endpoints, PASI-75 and PGA clear/minimal at Week 12, were both statistically significant in favor of tildrakizumab 200 mg and 100 mg compared with placebo (p<0.001). The strong design and positive primary results provide high-quality evidence of treatment benefit.
Next expected readout: September 2028 · NCT05390515 (registry estimate)
Reported efficacy
Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)); Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Base Study) (Baseline and Week 12 (or end of trial if prior to Week 12)); Number of Participants Experiencing an Adverse Event Up to Week 12 (Base Study) (Up to 12 weeks); Number of Participants Discontinuing Study Drug Due to an Adverse Event Up to Week 12 (Base Study) (Up to 12 weeks); Number of Participants Discontinuing Study Drug Due to a Drug-Related Adverse Event (Base Study) (Up to 12 weeks): Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)): Tildrakizumab 200 mg (Part 1) 62.3% | Tildrakizumab 100 mg (Part 1) 63.8% vs Placebo (Part 1) 5.8% (met)
Result source: NCT01722331
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | guselkumab | tildrakizumab |
|---|---|---|
| PASI 75 | 84.1% vs 6.3%+77.8 vs placeboNCT0232521911 other results
| 66.3% vs 4.4%+61.9 vs placeboNCT0122573131 other results
|
| PASI 90 | 70% vs 2.4%+67.6 vs placeboNCT0220724410 other results
| 38.6% vs 2.4%+36.2 vs placeboNCT012257313 other results
|
| PASI 100 | 50% vs 0%+50 vs placeboNCT029053313 other results
| 14.8% vs 0%+14.8 vs placeboNCT012257313 other results
|
| sPGA 0/1 | 85.7% vs 7.1%+78.6 vs placeboNCT014835994 other results
| 61.8% vs 2.2%+59.6 vs placeboNCT012257313 other results
|
| DLQI, change | -11.2 vs -2.6−8.6 vs placeboNCT0220724410 other results
| -8.5 vs 1−9.5 vs placeboNCT012257313 other results
|
PASI 75
- guselkumab
- 84.1% vs 6.3%+77.8 vs placeboNCT02325219
11 other results
- 89.2% vs 6.3% NCT02325219
- 86.3% vs 68.5% NCT02207244
- 92.7% vs 92.8% NCT03090100
- 89.3% vs 91.6% NCT03090100
- 91.2% vs 73.1% NCT02207231
- 78.6% vs 4.8% NCT01483599
- 81% vs 4.8% NCT01483599
- 81% vs 4.8% NCT01483599
- 75.6% vs 4.8% NCT01483599
- 43.9% vs 4.8% NCT01483599
- 5.1% vs 22.9% NCT03573323
- tildrakizumab
- 66.3% vs 4.4%+61.9 vs placeboNCT01225731
31 other results
- 74.4% vs 4.4% NCT01225731
- 64.4% vs 4.4% NCT01225731
- 33.3% vs 4.4% NCT01225731
- 67.0% vs 4.9% NCT01225731
- 60.7% vs 4.4% NCT01225731
- 61.4% vs 4.8% NCT01225731
- 47.1% vs 4.7% NCT01225731
- 25% vs 2.3% NCT01225731
- 11.2% vs 0% NCT01225731
- 1.1% vs 0% NCT01225731
- 76.2% vs 4.9% NCT01225731
- 72.1% vs 4.4% NCT01225731
- 73.5% vs 4.8% NCT01225731
- 61.5% vs 4.7% NCT01225731
- 30.9% vs 2.3% NCT01225731
- 3.5% vs 0% NCT01225731
- 0% vs 0% NCT01225731
- 65.5% vs 4.9% NCT01225731
- 58.9% vs 4.4% NCT01225731
- 59.8% vs 4.8% NCT01225731
- 35.2% vs 4.7% NCT01225731
- 20.9% vs 2.3% NCT01225731
- 11.2% vs 0% NCT01225731
- 1.1% vs 0% NCT01225731
- 35% vs 4.9% NCT01225731
- 23.8% vs 4.4% NCT01225731
- 25% vs 4.8% NCT01225731
- 12.5% vs 4.7% NCT01225731
- 12.5% vs 2.3% NCT01225731
- 0% vs 0% NCT01225731
- 0% vs 0% NCT01225731
PASI 90
- guselkumab
- 70% vs 2.4%+67.6 vs placeboNCT02207244
10 other results
- 73.3% vs 2.9% NCT02207231
- 69.8% vs 0% NCT02325219
- 70.8% vs 0% NCT02325219
- 75.8% vs 0% NCT02905331
- 70% vs 46.8% NCT02207244
- 78.5% vs 79.6% NCT03090100
- 69.1% vs 76.1% NCT03090100
- 73.3% vs 49.7% NCT02207231
- 35.9% vs 58.5% NCT03573323
- 7.9% vs 21% NCT03573323
- tildrakizumab
- 38.6% vs 2.4%+36.2 vs placeboNCT01225731
3 other results
- 52.4% vs 2.4% NCT01225731
- 25.3% vs 2.4% NCT01225731
- 12.5% vs 2.4% NCT01225731
PASI 100
- guselkumab
- 50% vs 0%+50 vs placeboNCT02905331
3 other results
- 24.9% vs 41.3% NCT03573323
- 13.6% vs 29.6% NCT03573323
- 1.4% vs 6.7% NCT03573323
- tildrakizumab
- 14.8% vs 0%+14.8 vs placeboNCT01225731
3 other results
- 16.7% vs 0% NCT01225731
- 9.2% vs 0% NCT01225731
- 5% vs 0% NCT01225731
sPGA 0/1
- guselkumab
- 85.7% vs 7.1%+78.6 vs placeboNCT01483599
4 other results
- 78.6% vs 7.1% NCT01483599
- 83.3% vs 7.1% NCT01483599
- 61% vs 7.1% NCT01483599
- 34.1% vs 7.1% NCT01483599
- tildrakizumab
- 61.8% vs 2.2%+59.6 vs placeboNCT01225731
3 other results
- 74.4% vs 2.2% NCT01225731
- 57.8% vs 2.2% NCT01225731
- 33.3% vs 2.2% NCT01225731
DLQI, change
- guselkumab
- -11.2 vs -2.6−8.6 vs placeboNCT02207244
10 other results
- -11.2 vs -0.6 NCT02207231
- -8.5 vs -0.8 NCT02325219
- -7 vs -0.4 NCT02325219
- -8.3 vs -0.8 NCT02325219
- -7.5 vs -0.4 NCT02325219
- -10.8 vs -2.3 NCT01483599
- -11.1 vs -2.3 NCT01483599
- -11.4 vs -2.3 NCT01483599
- -10.3 vs -2.3 NCT01483599
- -6.2 vs -2.3 NCT01483599
- tildrakizumab
- -8.5 vs 1−9.5 vs placeboNCT01225731
3 other results
- -8.8 vs 1 NCT01225731
- -9.2 vs 1 NCT01225731
- -4.9 vs 1 NCT01225731
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety
Coverage. guselkumab: 12 of 12 rows · tildrakizumab: 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | guselkumab Rows use multiple source trials | tildrakizumab Rows use multiple source trials |
|---|---|---|
| BSA absolute change · percentage points No placebo or comparator arm | -25.1% (n=141) @ 52wk100 mg Q8Wa,b,c,d NCT03818035 · Phase 3 · registry result, not featured evidence show 2 more doses-24.8% (n=492) @ 52wk100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence -24.3% (n=142) @ 52wk100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence | -11.5% (n=55) @ 52wk100 mgb,c,d NCT03718299 · Phase 4 · registry result, not featured evidence |
| DLQI absolute change · score No placebo or comparator arm | 5.3 score @ 100wkb,c,d,e NCT02951533 · Phase 3 · registry result, not featured evidence | -8 score @ 64wk100 mgb,c,d,e NCT03718299 · Phase 4 · registry result, not featured evidence |
| DLQI 0/1 responder rate · % of participants No placebo or comparator arm | 76.7% (n=60) @ 52wk100 mga,b,c,d NCT02325219 · Phase 3 · registry result, not featured evidence show 1 more dose73.4% (n=64) @ 52wk50 mg NCT02325219 · Phase 3 · registry result, not featured evidence | 56.3% (n=55) @ 52wk100 mgb,c,d NCT03718299 · Phase 4 · registry result, not featured evidence |
| DLQI 5 Point Improvement responder rate · % of participants Induction | 69.8% (n=63) vs 20.3% (n=64) placebo @ 16wk100 mga,f,c,d NCT02325219 · Phase 3 · registry result, not featured evidence show 1 more dose67.7% (n=65) vs 20.3% (n=64) placebo @ 16wk50 mg NCT02325219 · Phase 3 · registry result, not featured evidence | 64.77% (n=88) vs 19.05% (n=42) placebo @ 16wk100 mga,f,c,d NCT01225731 · Phase 2 · registry result, not featured evidence show 3 more doses73.49% (n=83) vs 19.05% (n=42) placebo @ 16wk200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 70.11% (n=87) vs 19.05% (n=42) placebo @ 16wk25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 52.5% (n=40) vs 19.05% (n=42) placebo @ 16wk5 mg NCT01225731 · Phase 2 · registry result, not featured evidence |
| DLQI 5 Point Improvement responder rate · % of participants No placebo or comparator arm | 71.4% (n=63) @ 52wk100 mga,b,c,d NCT02325219 · Phase 3 · registry result, not featured evidence show 1 more dose72.3% (n=65) @ 52wk50 mg NCT02325219 · Phase 3 · registry result, not featured evidence | 82.5% (n=55) @ 52wk100 mgb,c,d NCT03718299 · Phase 4 · registry result, not featured evidence |
| PASI absolute change · score Induction | -23.9 vs -0.5 placebo score @ 16wk100 mga,f,c,d NCT02325219 · Phase 3 · registry result, not featured evidence show 1 more dose-22.6 vs -0.5 placebo score @ 16wk50 mg NCT02325219 · Phase 3 · registry result, not featured evidence | -14.9 vs -2.4 placebo score @ 16wk100 mga,f,c,d NCT01225731 · Phase 2 · registry result, not featured evidence show 3 more doses-15.6 vs -2.4 placebo score @ 16wk200 mg NCT01225731 · Phase 2 · registry result, not featured evidence -14.6 vs -2.4 placebo score @ 16wk25 mg NCT01225731 · Phase 2 · registry result, not featured evidence -10 vs -2.4 placebo score @ 16wk5 mg NCT01225731 · Phase 2 · registry result, not featured evidence |
| PASI absolute change · score No placebo or comparator arm | -24.6 score @ 52wk100 mga,b,c,d NCT02325219 · Phase 3 · registry result, not featured evidence show 1 more dose-23.5 score @ 52wk50 mg NCT02325219 · Phase 3 · registry result, not featured evidence | -10 score @ 52wk100 mgb,c,d NCT03718299 · Phase 4 · registry result, not featured evidence |
| PASI 50 responder rate · % of participants Induction | 9.3% (n=507) vs 27.5% (n=520) Ixekizumab @ 1wkg,c,d,h NCT03573323 · Phase 4 · registry result, not featured evidence | 82.02% (n=89) vs 8.89% (n=45) placebo @ 16wk100 mga,g,c,d,h NCT01225731 · Phase 2 · registry result, not featured evidence show 3 more doses91.86% (n=86) vs 8.89% (n=45) placebo @ 16wk200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 82.22% (n=90) vs 8.89% (n=45) placebo @ 16wk25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 57.14% (n=42) vs 8.89% (n=45) placebo @ 16wk5 mg NCT01225731 · Phase 2 · registry result, not featured evidence |
| Dropout rate | —100 mgi NCT02203032 · Phase 3 show 42 more results3.6%100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207231 · Phase 3 —100 mg NCT02207231 · Phase 3 1.6%Guselkumab NCT02905331 · Phase 3 —Guselkumab (Week 0-16) NCT02905331 · Phase 3 —Guselkumab (Week 16-40) NCT02905331 · Phase 3 9.5% NCT03573323 · Phase 4 · registry result, not featured evidence 13%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 4.9%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 7.6%100 mg NCT06039189 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT03818035 · Phase 3 · registry result, not featured evidence 6.6%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.6%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence —50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 3.1%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence —Part I/IIa (Week 0 to Week 32): Gu NCT02951533 · Phase 3 · registry result, not featured evidence —Part III (Week 64 Through Week 100 NCT02951533 · Phase 3 · registry result, not featured evidence —Part IIb (Week 32 Through Week 56) NCT02951533 · Phase 3 · registry result, not featured evidence 5.1%100 mg NCT03090100 · Phase 3 · registry result, not featured evidence —100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 4.8%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence —50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 7.1%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence —200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 9.5%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence —15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence —5 mg NCT01483599 · Phase 2 · registry result, not featured evidence 7.3%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence | —100 mgi NCT01729754 · Phase 3 · monotherapy show 24 more results—200 mg NCT01729754 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy 15.7%100 mg NCT03897075 · Phase 3 —100 mg NCT03897075 · Phase 3 16.7% NCT04271540 · Phase 4 · registry result, not featured evidence 0% NCT04541329 · Phase 4 · registry result, not featured evidence 18.2%100 mg NCT03718299 · Phase 4 · registry result, not featured evidence 1.1%100 mg NCT01225731 · Phase 2 · registry result, not featured evidence —100 mg NCT01225731 · Phase 2 · registry result, not featured evidence —100 mg NCT01225731 · Phase 2 · registry result, not featured evidence 2.3%200 mg NCT01225731 · Phase 2 · registry result, not featured evidence —200 mg NCT01225731 · Phase 2 · registry result, not featured evidence —200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 5.4%25 mg NCT01225731 · Phase 2 · registry result, not featured evidence —25 mg NCT01225731 · Phase 2 · registry result, not featured evidence —25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 4.8%5 mg NCT01225731 · Phase 2 · registry result, not featured evidence —5 mg NCT01225731 · Phase 2 · registry result, not featured evidence —5 mg NCT01225731 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —100 mgi NCT02203032 · Phase 3 show 42 more results1.8%100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207231 · Phase 3 —100 mg NCT02207231 · Phase 3 0%Guselkumab NCT02905331 · Phase 3 —Guselkumab (Week 0-16) NCT02905331 · Phase 3 —Guselkumab (Week 16-40) NCT02905331 · Phase 3 1.6% NCT03573323 · Phase 4 · registry result, not featured evidence 1.3%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 0%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 0%100 mg NCT06039189 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT03818035 · Phase 3 · registry result, not featured evidence 1.9%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 0%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence —50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.5%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence —Part I/IIa (Week 0 to Week 32): Gu NCT02951533 · Phase 3 · registry result, not featured evidence —Part III (Week 64 Through Week 100 NCT02951533 · Phase 3 · registry result, not featured evidence —Part IIb (Week 32 Through Week 56) NCT02951533 · Phase 3 · registry result, not featured evidence 1.7%100 mg NCT03090100 · Phase 3 · registry result, not featured evidence —100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 2.4%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence —50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 2.4%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence —200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 9.5%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence —15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence —5 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence | —100 mgi NCT01729754 · Phase 3 · monotherapy show 24 more results—200 mg NCT01729754 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT03897075 · Phase 3 —100 mg NCT03897075 · Phase 3 — NCT04271540 · Phase 4 · registry result, not featured evidence — NCT04541329 · Phase 4 · registry result, not featured evidence 1.8%100 mg NCT03718299 · Phase 4 · registry result, not featured evidence 1.1%100 mg NCT01225731 · Phase 2 · registry result, not featured evidence —100 mg NCT01225731 · Phase 2 · registry result, not featured evidence —100 mg NCT01225731 · Phase 2 · registry result, not featured evidence 1.2%200 mg NCT01225731 · Phase 2 · registry result, not featured evidence —200 mg NCT01225731 · Phase 2 · registry result, not featured evidence —200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 2.2%25 mg NCT01225731 · Phase 2 · registry result, not featured evidence —25 mg NCT01225731 · Phase 2 · registry result, not featured evidence —25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 2.4%5 mg NCT01225731 · Phase 2 · registry result, not featured evidence —5 mg NCT01225731 · Phase 2 · registry result, not featured evidence —5 mg NCT01225731 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 6.7%100 mgi NCT02203032 · Phase 3 show 42 more results1.6%100 mg NCT02207244 · Phase 3 2.1%100 mg NCT02207244 · Phase 3 14%100 mg NCT02207244 · Phase 3 2.5%100 mg NCT02207231 · Phase 3 2.4%100 mg NCT02207231 · Phase 3 —Guselkumab NCT02905331 · Phase 3 3.2%Guselkumab (Week 0-16) NCT02905331 · Phase 3 1.6%Guselkumab (Week 16-40) NCT02905331 · Phase 3 3.2% NCT03573323 · Phase 4 · registry result, not featured evidence 3.9%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 3.7%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 5.3%100 mg NCT06039189 · Phase 3 · registry result, not featured evidence 4.7%100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 6.3%100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 2.2%100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 3.5%100 mg NCT03818035 · Phase 3 · registry result, not featured evidence 4.3%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 0%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence 4%100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence 6.6%100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence 9.7%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.6%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 9.5%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.5%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 5%Part I/IIa (Week 0 to Week 32): Gu NCT02951533 · Phase 3 · registry result, not featured evidence 0%Part III (Week 64 Through Week 100 NCT02951533 · Phase 3 · registry result, not featured evidence 5.5%Part IIb (Week 32 Through Week 56) NCT02951533 · Phase 3 · registry result, not featured evidence 6.2%100 mg NCT03090100 · Phase 3 · registry result, not featured evidence 5%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 7.1%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 5.3%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence | 6.2%100 mgi NCT01729754 · Phase 3 · monotherapy show 24 more results4.9%200 mg NCT01729754 · Phase 3 · monotherapy 1.6%100 mg NCT01722331 · Phase 3 · monotherapy 1.9%100 mg NCT01722331 · Phase 3 · monotherapy 4.4%100 mg NCT01722331 · Phase 3 · monotherapy 2.6%200 mg NCT01722331 · Phase 3 · monotherapy 2.2%200 mg NCT01722331 · Phase 3 · monotherapy 5.8%200 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT03897075 · Phase 3 5.9%100 mg NCT03897075 · Phase 3 0% NCT04271540 · Phase 4 · registry result, not featured evidence 0% NCT04541329 · Phase 4 · registry result, not featured evidence 7.3%100 mg NCT03718299 · Phase 4 · registry result, not featured evidence 1.1%100 mg NCT01225731 · Phase 2 · registry result, not featured evidence 3.9%100 mg NCT01225731 · Phase 2 · registry result, not featured evidence 1.5%100 mg NCT01225731 · Phase 2 · registry result, not featured evidence 2.3%200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 3.8%200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 2.7%200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 1.1%25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 5.3%25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 1.1%25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01225731 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01225731 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01225731 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 37 more results100 mg nasopharyngitis 7.1% (placebo 6.5%) headache 5.1% (placebo 2.8%) upper respiratory tract infection 3.2% (placebo 4%) NCT02207244 · Phase 3 100 mg nasopharyngitis 3.7% (placebo 6.5%) upper respiratory tract infection 2.5% (placebo 4%) arthralgia 1.7% (placebo 2.4%) NCT02207244 · Phase 3 100 mg nasopharyngitis 30% (placebo 6.5%) upper respiratory tract infection 23.5% (placebo 4%) arthralgia 9.7% (placebo 2.4%) NCT02207244 · Phase 3 100 mg nasopharyngitis 20.1% (placebo 9.8%) upper respiratory tract infection 9.6% (placebo 5.2%) gastroenteritis 3.4% (placebo 1.1%) NCT02207231 · Phase 3 100 mg nasopharyngitis 9.1% (placebo 9.8%) upper respiratory tract infection 7.6% (placebo 5.2%) headache 4.3% (placebo 4%) NCT02207231 · Phase 3 injection site pain 40.3% (placebo 43.8%) injection site coldness 22.6% (placebo 18.8%) injection site pruritus 12.9% (placebo 12.5%) NCT02905331 · Phase 3 injection site pain 18% (placebo 43.8%) injection site coldness 11.5% (placebo 18.8%) viral upper respiratory tract infection 9.8% (placebo 0%) NCT02905331 · Phase 3 upper respiratory tract infection 8.1% nasopharyngitis 5.3% injection site reaction 1.2% NCT03573323 · Phase 4 · registry result, not featured evidence 100 mg upper respiratory tract infection 16.9% (placebo 3.8%) nasopharyngitis 11.7% (placebo 3.8%) covid-19 6.5% (placebo 0%) NCT05272150 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 24.7% (placebo 3.8%) covid-19 16% (placebo 0%) arthralgia 7.4% (placebo 0%) NCT05272150 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 15.1% (placebo 2.7%) nasopharyngitis 6.7% (placebo 7.1%) covid-19 4.4% (placebo 0.9%) NCT06039189 · Phase 3 · registry result, not featured evidence 100 mg Q8W nasopharyngitis 17.6% headache 5.4% back pain 4.1% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q8W nasopharyngitis 18.5% hypertension 5.9% arthralgia 5.5% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q8W covid-19 14.7% nasopharyngitis 12.5% psoriasis 7.4% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 14.1% covid-19 9.3% headache 5.7% NCT03818035 · Phase 3 · registry result, not featured evidence 100mg nasopharyngitis 24.3% headache 9% hypertension 5.5% NCT03818035 · Phase 3 · registry result, not featured evidence 100mg nail psoriasis 22.2% back pain 11.1% covid-19 11.1% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q16W nasopharyngitis 15.4% headache 6% back pain 5.4% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q16W nasopharyngitis 12.4% covid-19 8.8% psoriasis 8.8% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 50% (placebo 10.9%) eczema 11.3% (placebo 1.6%) injection site erythema 11.3% (placebo 1.6%) NCT02325219 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 12.7% (placebo 10.9%) dental caries 3.2% (placebo 1.6%) upper respiratory tract infection 3.2% (placebo 1.6%) NCT02325219 · Phase 3 · registry result, not featured evidence 50 mg nasopharyngitis 60.3% (placebo 10.9%) arthralgia 14.3% (placebo 0%) influenza 14.3% (placebo 1.6%) NCT02325219 · Phase 3 · registry result, not featured evidence 50 mg nasopharyngitis 21.5% (placebo 10.9%) alopecia 3.1% (placebo 0%) arthralgia 3.1% (placebo 0%) NCT02325219 · Phase 3 · registry result, not featured evidence nasopharyngitis 41.7% headache 15% diarrhoea 11.7% NCT02951533 · Phase 3 · registry result, not featured evidence aspartate aminotransferase increased 2.8% tooth infection 2.8% abdominal discomfort 0% NCT02951533 · Phase 3 · registry result, not featured evidence nasopharyngitis 50.9% bronchitis 9.1% alanine aminotransferase increased 5.5% NCT02951533 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 22.1% upper respiratory tract infection 15.5% headache 9% NCT03090100 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 10% (placebo 2.4%) upper respiratory tract infection 7.5% (placebo 2.4%) back pain 5% (placebo 0%) NCT01483599 · Phase 2 · registry result, not featured evidence 100 mg back pain 4.8% (placebo 0%) headache 4.8% (placebo 2.4%) sinusitis 4.8% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 50 mg nasopharyngitis 17.9% (placebo 2.4%) back pain 2.6% (placebo 0%) headache 2.6% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 50 mg hypertension 7.1% (placebo 2.4%) fatigue 4.8% (placebo 7.1%) arthralgia 2.4% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 13.2% (placebo 2.4%) cough 5.3% (placebo 2.4%) upper respiratory tract infection 5.3% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 200 mg upper respiratory tract infection 7.3% (placebo 2.4%) cough 4.9% (placebo 2.4%) nasopharyngitis 4.9% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 15 mg back pain 2.4% (placebo 0%) nasopharyngitis 2.4% (placebo 2.4%) sinusitis 2.4% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 15 mg headache 9.8% (placebo 2.4%) nasopharyngitis 9.8% (placebo 2.4%) back pain 2.4% (placebo 0%) NCT01483599 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 15.8% (placebo 2.4%) upper respiratory tract infection 10.5% (placebo 2.4%) arthralgia 5.3% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 14.6% (placebo 2.4%) back pain 7.3% (placebo 0%) headache 7.3% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence | 100 mgi nasopharyngitis 23% (placebo 7.7%) headache 6% (placebo 3.8%) arthralgia 5.3% (placebo 1.9%) NCT01729754 · Phase 3 · monotherapy show 22 more results200 mg nasopharyngitis 22.6% (placebo 7.7%) headache 5.7% (placebo 3.8%) upper respiratory tract infection 5.1% (placebo 0.6%) NCT01729754 · Phase 3 · monotherapy 100 mg nasopharyngitis 7.8% (placebo 5.2%) upper respiratory tract infection 3.2% (placebo 5.8%) psoriasis 0.6% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 100 mg nasopharyngitis 6.4% (placebo 5.2%) upper respiratory tract infection 4.3% (placebo 5.8%) psoriasis 0.5% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 100 mg nasopharyngitis 15.2% (placebo 5.2%) upper respiratory tract infection 8.2% (placebo 5.8%) psoriasis 2.8% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 200 mg nasopharyngitis 6.5% (placebo 5.2%) upper respiratory tract infection 4.9% (placebo 5.8%) psoriasis 0% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 200 mg upper respiratory tract infection 5.4% (placebo 5.8%) nasopharyngitis 4.6% (placebo 5.2%) psoriasis 0.8% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 200 mg nasopharyngitis 12.2% (placebo 5.2%) upper respiratory tract infection 10.3% (placebo 5.8%) psoriasis 2.5% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 100 mg covid-19 11.8% (placebo 10.4%) skin and subcutaneous tissue disorders 9.8% (placebo 4.2%) upper respiratory tract infection 9.8% (placebo 8.3%) NCT03897075 · Phase 3 covid infection 9.7% NCT04271540 · Phase 4 · registry result, not featured evidence 100 mg psoriasis 12.7% hypertension 9.1% dermatitis 5.5% NCT03718299 · Phase 4 · registry result, not featured evidence 100 mg nasopharyngitis 14.6% (placebo 20%) diarrhoea 6.7% (placebo 6.7%) headache 6.7% (placebo 8.9%) NCT01225731 · Phase 2 · registry result, not featured evidence 100 mg nasopharyngitis 22.2% (placebo 20%) headache 8.5% (placebo 8.9%) back pain 5.2% (placebo 0%) NCT01225731 · Phase 2 · registry result, not featured evidence 100 mg nasopharyngitis 8.8% (placebo 20%) back pain 3.6% (placebo 0%) headache 3.6% (placebo 8.9%) NCT01225731 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 12.8% (placebo 20%) headache 8.1% (placebo 8.9%) pruritus 4.7% (placebo 8.9%) NCT01225731 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 16.5% (placebo 20%) gastroenteritis 6.3% (placebo 2.2%) upper respiratory tract infection 5.1% (placebo 0%) NCT01225731 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 6.7% (placebo 20%) upper respiratory tract infection 4% (placebo 0%) bronchiitis 2.7% (placebo 4.4%) NCT01225731 · Phase 2 · registry result, not featured evidence 25 mg nasopharyngitis 13.2% (placebo 20%) diarrhoea 5.5% (placebo 6.7%) headache 5.5% (placebo 8.9%) NCT01225731 · Phase 2 · registry result, not featured evidence 25 mg nasopharyngitis 25.5% (placebo 20%) gastroenteritis 5.3% (placebo 2.2%) back pain 4.3% (placebo 0%) NCT01225731 · Phase 2 · registry result, not featured evidence 25 mg nasopharyngitis 6.9% (placebo 20%) back pain 3.4% (placebo 0%) bronchiitis 2.3% (placebo 4.4%) NCT01225731 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 16.7% (placebo 20%) bronchiitis 7.1% (placebo 4.4%) cough 7.1% (placebo 4.4%) NCT01225731 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 23.1% (placebo 20%) acute tonsilitis 7.7% (placebo 0%) blood pressure systolic increased 7.7% (placebo 0%) NCT01225731 · Phase 2 · registry result, not featured evidence 5 mg abdominal pain upper 8.3% (placebo 0%) back pain 8.3% (placebo 0%) dyspnoea 8.3% (placebo 0%) NCT01225731 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 4.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 100 weeks versus 64 weeks.
- fTrial phases differ: Phase 3 versus Phase 2.
- gTrial phases differ: Phase 4 versus Phase 2.
- hAssessment timepoints differ: 1 weeks versus 16 weeks.
- iPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
guselkumab
show 13 more results
show 5 more results
show 5 more results
show 1 more result
show 1 more result
show 1 more result
+ 86 further endpoints in the CSV export.
tildrakizumab
show 5 more results
show 5 more results
show 11 more results
show 11 more results
show 5 more results
show 11 more results
show 5 more results
show 11 more results
show 5 more results
show 11 more results
show 5 more results
show 11 more results
+ 20 further endpoints in the CSV export.
Psoriatic Arthritis
Shared mechanism: IL-23 p19 · full Psoriatic Arthritis pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
NCT03162796 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial, and both guselkumab doses beat placebo on the week-24 ACR20 joint response (p<0.001). The protocol's sample-size calculation called for 360 patients, and 383 were enrolled.
Next expected readout: April 2027 · NCT04929210 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (At Week 24): Group 1: Guselkumab 100 mg q8w 68.3 percentage of participants | Group 2: Guselkumab 100 mg q4w 66.6 percentage of participants | Group 3: Placebo Followed by Guselkumab 47 percentage of participants (met)
Result source: NCT04882098
tildrakizumab · Ilumya
Marketed by Sun Pharmaceutical Industries and partners
NCT04314544 · Phase 3 · completed
The study randomized 508 participants to tildrakizumab or placebo, with outcome assessors masked, and used the clinical ACR20 response as its primary endpoint. However, no results are posted, so whether the primary endpoint was met or missed is unknown.
Next expected readout: December 2028 · NCT04991116 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Psoriatic Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | guselkumab | tildrakizumab |
|---|---|---|
| ACR20 | 52% vs 22.2%+29.8 vs placeboNCT0316279627 other results
| 0.8% vs 0.5%+0.3 vs placeboNCT029806923 other results
|
| ACR50 | 43.4% vs 36.5%+6.9 vs placeboNCT0316279626 other results
| —Not posted · NCT04314544 |
| PASI 75 | 80% vs 84.8%−4.8 vs placeboNCT031627968 other results
| —Not posted · NCT04314544 |
| Minimal disease activity | 33.9% vs 31.1%+2.8 vs placeboNCT031627969 other results
| —Not posted · NCT04314544 |
| HAQ-DI, change | -0.4 vs -0.4−0.1 vs placeboNCT0316279630 other results
| —Not posted · NCT04314544 |
ACR20
- guselkumab
- 52% vs 22.2%+29.8 vs placeboNCT03162796
27 other results
- 59.4% vs 22.2% NCT03162796
- 52% vs 22.2% NCT03162796
- 59.4% vs 22.2% NCT03162796
- 54.5% vs 27.2% NCT03162796
- 60.8% vs 27.2% NCT03162796
- 51.2% vs 30.2% NCT03162796
- 62.5% vs 30.2% NCT03162796
- 68.9% vs 50% NCT03162796
- 74.4% vs 50% NCT03162796
- 52% vs 25.4% NCT03162796
- 60.2% vs 25.4% NCT03162796
- 52% vs 25.4% NCT03162796
- 60.2% vs 25.4% NCT03162796
- 43.3% vs 27% NCT03162796
- 53.1% vs 27% NCT03162796
- 70.3% vs 56.9% NCT03162796
- 71.1% vs 56.9% NCT03162796
- 36.2% vs 18.3% NCT03162796
- 39.1% vs 18.3% NCT03162796
- 15.7% vs 7.9% NCT03162796
- 20.3% vs 7.9% NCT03162796
- 73.5% vs 61.7% NCT03162796
- 72% vs 61.7% NCT03162796
- 67.9% vs 68.3% NCT03162796
- 75.8% vs 68.3% NCT03162796
- 58% vs 18.4% NCT02319759
- 60% vs 16.3% NCT02319759
- tildrakizumab
- 0.8% vs 0.5%+0.3 vs placeboNCT02980692
3 other results
- 0.8% vs 0.5% NCT02980692
- 0.7% vs 0.5% NCT02980692
- 0.7% vs 0.5% NCT02980692
ACR50
- guselkumab
- 43.4% vs 36.5%+6.9 vs placeboNCT03162796
26 other results
- 55.6% vs 36.5% NCT03162796
- 51.3% vs 30.8% NCT03162796
- 46% vs 30.8% NCT03162796
- 47.1% vs 32.7% NCT03162796
- 44.6% vs 32.7% NCT03162796
- 42.6% vs 21.4% NCT03162796
- 39.2% vs 21.4% NCT03162796
- 29.9% vs 8.7% NCT03162796
- 35.9% vs 8.7% NCT03162796
- 29.9% vs 8.7% NCT03162796
- 35.9% vs 8.7% NCT03162796
- 30.9% vs 9.6% NCT03162796
- 36.8% vs 9.6% NCT03162796
- 29.1% vs 13.5% NCT03162796
- 37.5% vs 13.5% NCT03162796
- 22.8% vs 12.7% NCT03162796
- 26.6% vs 12.7% NCT03162796
- 22.8% vs 12.7% NCT03162796
- 26.6% vs 12.7% NCT03162796
- 20.5% vs 10.3% NCT03162796
- 24.2% vs 10.3% NCT03162796
- 7.9% vs 7.9% NCT03162796
- 10.9% vs 7.9% NCT03162796
- 1.6% vs 2.4% NCT03162796
- 3.1% vs 2.4% NCT03162796
- 34% vs 10.2% NCT02319759
- tildrakizumab
- —Not posted · NCT04314544
PASI 75
- guselkumab
- 80% vs 84.8%−4.8 vs placeboNCT03162796
8 other results
- 94.3% vs 84.8% NCT03162796
- 75.6% vs 14.1% NCT03162796
- 86.5% vs 14.1% NCT03162796
- 76.5% vs 20.6% NCT03162796
- 87.5% vs 20.6% NCT03162796
- 63.4% vs 20.5% NCT03162796
- 73% vs 20.5% NCT03162796
- 78.6% vs 12.5% NCT02319759
- tildrakizumab
- —Not posted · NCT04314544
Minimal disease activity
- guselkumab
- 33.9% vs 31.1%+2.8 vs placeboNCT03162796
9 other results
- 40.3% vs 31.1% NCT03162796
- 22.8% vs 11.1% NCT03162796
- 30.5% vs 11.1% NCT03162796
- 23.6% vs 12.3% NCT03162796
- 31.2% vs 12.3% NCT03162796
- 15.7% vs 7.1% NCT03162796
- 18% vs 7.1% NCT03162796
- 23% vs 2% NCT02319759
- 18% vs 0% NCT02319759
- tildrakizumab
- —Not posted · NCT04314544
HAQ-DI, change
- guselkumab
- -0.4 vs -0.4−0.1 vs placeboNCT03162796
30 other results
- -0.5 vs -0.4 NCT03162796
- -0.5 vs -0.4 NCT03162796
- -0.4 vs -0.4 NCT03162796
- -0.4 vs -0.3 NCT03162796
- -0.4 vs -0.3 NCT03162796
- -0.4 vs -0.2 NCT03162796
- -0.4 vs -0.2 NCT03162796
- -0.3 vs -0.1 NCT03162796
- -0.4 vs -0.1 NCT03162796
- -0.3 vs -0.1 NCT03162796
- -0.4 vs -0.1 NCT03162796
- -0.3 vs -0.1 NCT03162796
- -0.4 vs -0.1 NCT03162796
- -0.3 vs -0.1 NCT03162796
- -0.4 vs -0.1 NCT03162796
- -0.3 vs -0.1 NCT03162796
- -0.3 vs -0.1 NCT03162796
- -0.2 vs -0.1 NCT03162796
- -0.3 vs -0.1 NCT03162796
- -0.2 vs -0.1 NCT03162796
- -0.2 vs -0.1 NCT03162796
- -0.1 vs 0.0 NCT03162796
- -0.1 vs 0.0 NCT03162796
- -0.4 vs -0.1 NCT02319759
- -0.4 vs -0.1 NCT02319759
- -0.4 vs -0.1 NCT02319759
- -0.4 vs -0.1 NCT02319759
- -0.3 vs -0.1 NCT02319759
- -0.3 vs -0.1 NCT02319759
- -0.2 vs -0.0 NCT02319759
- tildrakizumab
- —Not posted · NCT04314544
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety
Coverage. guselkumab: 14 of 14 rows · tildrakizumab: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | guselkumab Rows use multiple source trials | tildrakizumab |
|---|---|---|
| ACR20 responder rate · % of participants No placebo or comparator arm | 75.9% (n=234) @ 52wk100 mg q4wa,b,c,d NCT03158285 · Phase 3 show 3 more doses77% (n=227) @ 52wk100 mg q4w NCT03158285 · Phase 3 79.1% (n=240) @ 52wk100 mg q8w NCT03158285 · Phase 3 78.9% (n=232) @ 52wk100 mg q8w NCT03158285 · Phase 3 | 0.8667% (n=60) @ 52wkDose IIIa,b,c,d NCT02980692 · Phase 2 · registry result, not featured evidence show 3 more doses0.8133% (n=75) @ 52wkDose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence 0.9254% (n=67) @ 52wkI NCT02980692 · Phase 2 · registry result, not featured evidence 0.8906% (n=64) @ 52wkII NCT02980692 · Phase 2 · registry result, not featured evidence |
| ACR50 responder rate · % of participants No placebo or comparator arm | 49.1% (n=234) @ 52wk100 mg q4wa,b,c,d NCT03158285 · Phase 3 show 3 more doses49.6% (n=227) @ 52wk100 mg q4w NCT03158285 · Phase 3 51.3% (n=240) @ 52wk100 mg q8w NCT03158285 · Phase 3 50.9% (n=232) @ 52wk100 mg q8w NCT03158285 · Phase 3 | 0.7213% (n=77) @ 52wkDose IIIa,b,c,d NCT02980692 · Phase 2 · registry result, not featured evidence show 3 more doses0.68% (n=78) @ 52wkDose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence 0.791% (n=78) @ 52wkI NCT02980692 · Phase 2 · registry result, not featured evidence 0.75% (n=79) @ 52wkII NCT02980692 · Phase 2 · registry result, not featured evidence |
| ACR70 responder rate · % of participants No placebo or comparator arm | 28.1% (n=234) @ 52wk100 mg q4wa,b,c,d NCT03158285 · Phase 3 show 3 more doses28.3% (n=227) @ 52wk100 mg q4w NCT03158285 · Phase 3 29.5% (n=240) @ 52wk100 mg q8w NCT03158285 · Phase 3 29.7% (n=232) @ 52wk100 mg q8w NCT03158285 · Phase 3 | 0.3934% (n=77) @ 52wkDose IIIa,b,c,d NCT02980692 · Phase 2 · registry result, not featured evidence show 3 more doses0.4% (n=78) @ 52wkDose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence 0.5821% (n=78) @ 52wkI NCT02980692 · Phase 2 · registry result, not featured evidence 0.4844% (n=79) @ 52wkII NCT02980692 · Phase 2 · registry result, not featured evidence |
| Dactylitis absolute change · score | -5.82 vs -4.3 placebo score @ 24wk100 mg q4wa,b,c,d NCT03162796 · Phase 3 show 5 more doses-5.82 vs -4.3 placebo score @ 24wk100 mg q4w NCT03162796 · Phase 3 -6.6 vs -4 placebo score @ 24wk100 mg q4w NCT03162796 · Phase 3 -6.11 vs -4.3 placebo score @ 24wk100 mg q8w NCT03162796 · Phase 3 -6.11 vs -4.3 placebo score @ 24wk100 mg q8w NCT03162796 · Phase 3 -6.2 vs -4 placebo score @ 24wk100 mg q8w NCT03162796 · Phase 3 | -27.572 vs -24.706 placebo score @ 24wkDose IIIa,b,c,d NCT02980692 · Phase 2 · registry result, not featured evidence show 3 more doses-19.873 vs -24.706 placebo score @ 24wkDose IV NCT02980692 · Phase 2 · registry result, not featured evidence -22.987 vs -24.706 placebo score @ 24wkI NCT02980692 · Phase 2 · registry result, not featured evidence -25.123 vs -24.706 placebo score @ 24wkII NCT02980692 · Phase 2 · registry result, not featured evidence |
| Dactylitis absolute change · score No placebo or comparator arm | -7.4 score @ 52wk100 mg q4wa,b,c,d NCT03158285 · Phase 3 show 3 more doses-7.4 score @ 52wk100 mg q4w NCT03158285 · Phase 3 -7.3 score @ 52wk100 mg q8w NCT03158285 · Phase 3 -7.3 score @ 52wk100 mg q8w NCT03158285 · Phase 3 | -27.084 score @ 52wkDose IIIa,b,c,d NCT02980692 · Phase 2 · registry result, not featured evidence show 3 more doses-26.173 score @ 52wkDose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence -14.453 score @ 52wkI NCT02980692 · Phase 2 · registry result, not featured evidence -18.883 score @ 52wkII NCT02980692 · Phase 2 · registry result, not featured evidence |
| DAS28 (CRP responder rate · % of participants No placebo or comparator arm | 89.4% (n=234) @ 52wk100 mg q4wa,b,c,d NCT03158285 · Phase 3 show 3 more doses90.2% (n=227) @ 52wk100 mg q4w NCT03158285 · Phase 3 89.7% (n=240) @ 52wk100 mg q8w NCT03158285 · Phase 3 89.7% (n=232) @ 52wk100 mg q8w NCT03158285 · Phase 3 | 76.27% (n=77) @ 52wkDose IIIa,b,c,d NCT02980692 · Phase 2 · registry result, not featured evidence show 3 more doses71.05% (n=78) @ 52wkDose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence 85.07% (n=78) @ 52wkI NCT02980692 · Phase 2 · registry result, not featured evidence 81.25% (n=79) @ 52wkII NCT02980692 · Phase 2 · registry result, not featured evidence |
| Enthesitis absolute change · score | -1.75 vs -1.01 placebo score @ 24wk100 mg q4wa,b,c,d NCT03162796 · Phase 3 show 1 more dose-1.35 vs -1.01 placebo score @ 24wk100 mg q8w NCT03162796 · Phase 3 | -1.2 vs -0.8 placebo score @ 24wkDose IIIa,b,c,d NCT02980692 · Phase 2 · registry result, not featured evidence show 3 more doses-1.1 vs -0.8 placebo score @ 24wkDose IV NCT02980692 · Phase 2 · registry result, not featured evidence -1.3 vs -0.8 placebo score @ 24wkI NCT02980692 · Phase 2 · registry result, not featured evidence -0.9 vs -0.8 placebo score @ 24wkII NCT02980692 · Phase 2 · registry result, not featured evidence |
| Enthesitis absolute change · score No placebo or comparator arm | -2 score @ 52wk100 mg q4wa,b,c,d NCT03158285 · Phase 3 show 3 more doses-2.1 score @ 52wk100 mg q4w NCT03158285 · Phase 3 -1.9 score @ 52wk100 mg q8w NCT03158285 · Phase 3 -1.9 score @ 52wk100 mg q8w NCT03158285 · Phase 3 | -1.7 score @ 52wkDose IIIa,b,c,d NCT02980692 · Phase 2 · registry result, not featured evidence show 3 more doses-1.2 score @ 52wkDose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence -1.3 score @ 52wkI NCT02980692 · Phase 2 · registry result, not featured evidence -1 score @ 52wkII NCT02980692 · Phase 2 · registry result, not featured evidence |
| HAQ-DI absolute change · score No placebo or comparator arm | -0.5082 score @ 52wk100 mg q4wa,b,c,d NCT03158285 · Phase 3 show 3 more doses-0.5111 score @ 52wk100 mg q4w NCT03158285 · Phase 3 -0.4824 score @ 52wk100 mg q8w NCT03158285 · Phase 3 -0.4801 score @ 52wk100 mg q8w NCT03158285 · Phase 3 | -0.4857 score @ 52wkDose IIIa,b,c,d NCT02980692 · Phase 2 · registry result, not featured evidence show 3 more doses-0.4583 score @ 52wkDose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence -0.4869 score @ 52wkI NCT02980692 · Phase 2 · registry result, not featured evidence -0.543 score @ 52wkII NCT02980692 · Phase 2 · registry result, not featured evidence |
| MDA responder rate · % of participants No placebo or comparator arm | 36.8% (n=234) @ 52wk100 mg q4wa,b,c,d NCT03158285 · Phase 3 show 3 more doses37.2% (n=227) @ 52wk100 mg q4w NCT03158285 · Phase 3 32.9% (n=240) @ 52wk100 mg q8w NCT03158285 · Phase 3 32.8% (n=232) @ 52wk100 mg q8w NCT03158285 · Phase 3 | 45% (n=77) @ 52wkDose IIIa,b,c,d NCT02980692 · Phase 2 · registry result, not featured evidence show 3 more doses47.06% (n=78) @ 52wkDose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence 56.92% (n=78) @ 52wkI NCT02980692 · Phase 2 · registry result, not featured evidence 64.41% (n=79) @ 52wkII NCT02980692 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 2.3%100 mg q4we NCT03162796 · Phase 3 show 13 more results—100 mg q4w NCT03162796 · Phase 3 —100 mg q4w NCT03162796 · Phase 3 3.1%100 mg q8w NCT03162796 · Phase 3 —100 mg q8w NCT03162796 · Phase 3 —100 mg q8w NCT03162796 · Phase 3 3.7%100 mg q4w NCT03158285 · Phase 3 —100 mg q4w NCT03158285 · Phase 3 —100 mg q4w NCT03158285 · Phase 3 3.2%100 mg q8w NCT03158285 · Phase 3 —100 mg q8w NCT03158285 · Phase 3 —100 mg q8w NCT03158285 · Phase 3 1%Guselkumab (Week 0 to Week 56) NCT02319759 · Phase 2 · registry result, not featured evidence —Placebo to Guselkumab (Week 24 to NCT02319759 · Phase 2 · registry result, not featured evidence | 100%200 mg q12 Weekse NCT03552276 · Phase 2/3 · registry result, not featured evidence show 23 more results16.6%200 mg q12 Weeks switched to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q12 Weeks, to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 100%200 mg q4 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 14.8%200 mg q4 Weeks switched to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q4 Weeks, to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg, q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg, q4 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 32.7%100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —Dose III NCT02980692 · Phase 2 · registry result, not featured evidence —Dose IV NCT02980692 · Phase 2 · registry result, not featured evidence —II NCT02980692 · Phase 2 · registry result, not featured evidence —I NCT02980692 · Phase 2 · registry result, not featured evidence —Dose III NCT02980692 · Phase 2 · registry result, not featured evidence —II NCT02980692 · Phase 2 · registry result, not featured evidence —I NCT02980692 · Phase 2 · registry result, not featured evidence —Dose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence —Dose III NCT02980692 · Phase 2 · registry result, not featured evidence —II NCT02980692 · Phase 2 · registry result, not featured evidence —I NCT02980692 · Phase 2 · registry result, not featured evidence 22.1%Dose III NCT02980692 · Phase 2 · registry result, not featured evidence 9%Dose IV NCT02980692 · Phase 2 · registry result, not featured evidence 20.5%I NCT02980692 · Phase 2 · registry result, not featured evidence 19%II NCT02980692 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0.8%100 mg q4we NCT03162796 · Phase 3 show 13 more results—100 mg q4w NCT03162796 · Phase 3 —100 mg q4w NCT03162796 · Phase 3 2.4%100 mg q8w NCT03162796 · Phase 3 —100 mg q8w NCT03162796 · Phase 3 —100 mg q8w NCT03162796 · Phase 3 2.4%100 mg q4w NCT03158285 · Phase 3 —100 mg q4w NCT03158285 · Phase 3 —100 mg q4w NCT03158285 · Phase 3 0.8%100 mg q8w NCT03158285 · Phase 3 —100 mg q8w NCT03158285 · Phase 3 —100 mg q8w NCT03158285 · Phase 3 —Guselkumab (Week 0 to Week 56) NCT02319759 · Phase 2 · registry result, not featured evidence —Placebo to Guselkumab (Week 24 to NCT02319759 · Phase 2 · registry result, not featured evidence | —200 mg q12 Weekse NCT03552276 · Phase 2/3 · registry result, not featured evidence show 23 more results—200 mg q12 Weeks switched to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q12 Weeks, to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q4 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q4 Weeks switched to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q4 Weeks, to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg, q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg, q4 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —Dose III NCT02980692 · Phase 2 · registry result, not featured evidence —Dose IV NCT02980692 · Phase 2 · registry result, not featured evidence —II NCT02980692 · Phase 2 · registry result, not featured evidence —I NCT02980692 · Phase 2 · registry result, not featured evidence —Dose III NCT02980692 · Phase 2 · registry result, not featured evidence —II NCT02980692 · Phase 2 · registry result, not featured evidence —I NCT02980692 · Phase 2 · registry result, not featured evidence —Dose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence —Dose III NCT02980692 · Phase 2 · registry result, not featured evidence —II NCT02980692 · Phase 2 · registry result, not featured evidence —I NCT02980692 · Phase 2 · registry result, not featured evidence 1.3%Dose III NCT02980692 · Phase 2 · registry result, not featured evidence 2.6%Dose IV NCT02980692 · Phase 2 · registry result, not featured evidence 1.3%I NCT02980692 · Phase 2 · registry result, not featured evidence 2.5%II NCT02980692 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —100 mg q4we NCT03162796 · Phase 3 show 13 more results0%100 mg q4w NCT03162796 · Phase 3 3.1%100 mg q4w NCT03162796 · Phase 3 —100 mg q8w NCT03162796 · Phase 3 3.1%100 mg q8w NCT03162796 · Phase 3 6.3%100 mg q8w NCT03162796 · Phase 3 —100 mg q4w NCT03158285 · Phase 3 3.3%100 mg q4w NCT03158285 · Phase 3 9%100 mg q4w NCT03158285 · Phase 3 —100 mg q8w NCT03158285 · Phase 3 1.2%100 mg q8w NCT03158285 · Phase 3 8.9%100 mg q8w NCT03158285 · Phase 3 6%Guselkumab (Week 0 to Week 56) NCT02319759 · Phase 2 · registry result, not featured evidence 0%Placebo to Guselkumab (Week 24 to NCT02319759 · Phase 2 · registry result, not featured evidence | —200 mg q12 Weekse NCT03552276 · Phase 2/3 · registry result, not featured evidence show 23 more results—200 mg q12 Weeks switched to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 16.6%200 mg q12 Weeks, to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q4 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence —200 mg q4 Weeks switched to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 5.6%200 mg q4 Weeks, to 100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 9.1%200 mg, q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 60%200 mg, q4 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 14.3%100 mg q12 Weeks NCT03552276 · Phase 2/3 · registry result, not featured evidence 2.6%Dose III NCT02980692 · Phase 2 · registry result, not featured evidence 1.3%Dose IV NCT02980692 · Phase 2 · registry result, not featured evidence 2.5%II NCT02980692 · Phase 2 · registry result, not featured evidence 2.6%I NCT02980692 · Phase 2 · registry result, not featured evidence 0%Dose III NCT02980692 · Phase 2 · registry result, not featured evidence 0%II NCT02980692 · Phase 2 · registry result, not featured evidence 0%I NCT02980692 · Phase 2 · registry result, not featured evidence 3.8%Dose IV then SUNPG1623 II NCT02980692 · Phase 2 · registry result, not featured evidence 1.3%Dose III NCT02980692 · Phase 2 · registry result, not featured evidence 1.3%II NCT02980692 · Phase 2 · registry result, not featured evidence 3.8%I NCT02980692 · Phase 2 · registry result, not featured evidence —Dose III NCT02980692 · Phase 2 · registry result, not featured evidence —Dose IV NCT02980692 · Phase 2 · registry result, not featured evidence —I NCT02980692 · Phase 2 · registry result, not featured evidence —II NCT02980692 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 100 mg q4we upper respiratory tract infection 8.6% (placebo 6.3%) nasopharyngitis 5.5% (placebo 6.3%) enthesopathy 4.7% (placebo 4.8%) NCT03162796 · Phase 3 show 9 more results100 mg q4w upper respiratory tract infection 12.5% (placebo 6.3%) nasopharyngitis 10.9% (placebo 6.3%) alanine aminotransferase increased 7% (placebo 2.4%) NCT03162796 · Phase 3 100 mg q8w nasopharyngitis 12.6% (placebo 6.3%) aspartate aminotransferase increased 7.1% (placebo 2.4%) alanine aminotransferase increased 6.3% (placebo 2.4%) NCT03162796 · Phase 3 100 mg q8w nasopharyngitis 16.5% (placebo 6.3%) aspartate aminotransferase increased 8.7% (placebo 2.4%) upper respiratory tract infection 7.9% (placebo 6.3%) NCT03162796 · Phase 3 100 mg q4w alanine aminotransferase increased 9% (placebo 4.5%) upper respiratory tract infection 5.3% (placebo 3.3%) nasopharyngitis 4.9% (placebo 3.7%) NCT03158285 · Phase 3 100 mg q4w alanine aminotransferase increased 12.7% (placebo 4.5%) aspartate aminotransferase increased 9.4% (placebo 2.4%) nasopharyngitis 8.6% (placebo 3.7%) NCT03158285 · Phase 3 100 mg q8w alanine aminotransferase increased 6% (placebo 4.5%) aspartate aminotransferase increased 5.6% (placebo 2.4%) nasopharyngitis 4% (placebo 3.7%) NCT03158285 · Phase 3 100 mg q8w alanine aminotransferase increased 11.7% (placebo 4.5%) nasopharyngitis 10.1% (placebo 3.7%) upper respiratory tract infection 9.7% (placebo 3.3%) NCT03158285 · Phase 3 nasopharyngitis 10% (placebo 10.2%) leukopenia 5% (placebo 0%) alanine aminotransferase increased 4% (placebo 2%) NCT02319759 · Phase 2 · registry result, not featured evidence alanine aminotransferase increased 6.9% (placebo 2%) aspartate aminotransferase increased 6.9% (placebo 0%) leukopenia 3.4% (placebo 0%) NCT02319759 · Phase 2 · registry result, not featured evidence | 200 mg q12 Weeks, to 100 mg q12 Weekse covid-19 16.6% nasopharyngitis 13.9% urinary tract infection 11.9% NCT03552276 · Phase 2/3 · registry result, not featured evidence show 15 more results200 mg q4 Weeks, to 100 mg q12 Weeks covid-19 20.4% upper respiratory tract infection 16.7% nasopharyngitis 14.8% NCT03552276 · Phase 2/3 · registry result, not featured evidence 200 mg, q12 Weeks diarrhoea 18.2% arthralgia 13.6% arthritis 9.1% NCT03552276 · Phase 2/3 · registry result, not featured evidence 200 mg, q4 Weeks hypertension 40% abdominal abscess 20% alanine aminotransferase increased 20% NCT03552276 · Phase 2/3 · registry result, not featured evidence 100 mg q12 Weeks nasopharyngitis 14.3% upper respiratory tract infection 14.3% abdominal pain 8.2% NCT03552276 · Phase 2/3 · registry result, not featured evidence Dose III headache 6.5% (placebo 3.8%) nasopharyngitis 5.2% (placebo 6.3%) upper respiratory tract infection 3.9% (placebo 1.3%) NCT02980692 · Phase 2 · registry result, not featured evidence Dose IV diarrhoea 6.4% (placebo 0%) headache 6.4% (placebo 3.8%) nasopharyngitis 6.4% (placebo 6.3%) NCT02980692 · Phase 2 · registry result, not featured evidence II hypertension 7.6% (placebo 6.3%) sleep disorder 6.3% (placebo 1.3%) upper respiratory tract infection 5.1% (placebo 1.3%) NCT02980692 · Phase 2 · registry result, not featured evidence I nasopharyngitis 9% (placebo 6.3%) headache 5.1% (placebo 3.8%) hypertension 3.8% (placebo 6.3%) NCT02980692 · Phase 2 · registry result, not featured evidence Dose III headache 2.6% (placebo 3.8%) nasopharyngitis 2.6% (placebo 6.3%) upper respiratory tract infection 2.6% (placebo 1.3%) NCT02980692 · Phase 2 · registry result, not featured evidence II upper respiratory tract infection 5.1% (placebo 1.3%) headache 3.8% (placebo 3.8%) nasopharyngitis 2.5% (placebo 6.3%) NCT02980692 · Phase 2 · registry result, not featured evidence I hypertension 5.1% (placebo 6.3%) upper respiratory tract infection 3.8% (placebo 1.3%) aspartate aminotransferase increased 2.6% (placebo 0%) NCT02980692 · Phase 2 · registry result, not featured evidence Dose IV then SUNPG1623 II nasopharyngitis 9% (placebo 6.3%) upper respiratory tract infection 5.1% (placebo 1.3%) urinary tract infection 5.1% (placebo 3.8%) NCT02980692 · Phase 2 · registry result, not featured evidence Dose III headache 1.3% (placebo 3.8%) nasopharyngitis 1.3% (placebo 6.3%) upper respiratory tract infection 1.3% (placebo 1.3%) NCT02980692 · Phase 2 · registry result, not featured evidence II aspartate aminotransferase increased 1.3% (placebo 0%) diarrhoea 0% (placebo 0%) headache 0% (placebo 3.8%) NCT02980692 · Phase 2 · registry result, not featured evidence I headache 3.8% (placebo 3.8%) aspartate aminotransferase increased 2.6% (placebo 0%) nasopharyngitis 2.6% (placebo 6.3%) NCT02980692 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 2.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
guselkumab
show 30 more results
show 26 more results
show 5 more results
show 23 more results
show 23 more results
show 13 more results
show 17 more results
show 9 more results
show 13 more results
show 17 more results
show 27 more results
show 21 more results
+ 80 further endpoints in the CSV export.
tildrakizumab
show 27 more results
show 3 more results
show 27 more results
show 3 more results
show 27 more results
show 3 more results
show 27 more results
show 3 more results
show 27 more results
show 3 more results
show 27 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: guselkumab's landscape · tildrakizumab's landscape